Serina Therapeutics Reports Q3 2026 Financial Results and Advancement of SER-252 in Parkinson's Disease

Serina Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026. The company announced that the independent Safety Monitoring Committee (SMC) had reviewed safety and tolerability data from the first cohort of its registrational study of SER-252 in patients with advanced Parkinson's disease. The committee recommended advancing the study to the next dose level, and the company subsequently initiated dosing in Cohort 2.

SER-252 is an investigational apomorphine therapy developed using Serina's proprietary POZ platform technology, designed to provide continuous dopaminergic stimulation. The study is a randomized, double-blind, placebo-controlled trial with single-ascending-dose and multiple-ascending-dose components. The study is designed to evaluate safety, tolerability, and pharmacokinetics, with exploratory efficacy measures including MDS-UPDRS motor scores. Dosing in Cohort 2 is currently underway, and topline single-ascending-dose data are expected in the first half of 2027.

Regarding financial performance, Serina reported operating expenses of $8.0 million for the three months ended September 30, 2026, compared to $6.4 million in the same period in 2025. Research and development expenses were $4.6 million for the third quarter of 2026, compared to $3.6 million in 2025. General and administrative expenses were $3.3 million for the third quarter of 2026, compared to $2.7 million in 2025. The company reported a net loss attributable to common stockholders of $7.9 million, or $(0.31) per basic and diluted share, for the quarter ended September 30, 2026, compared to a net loss of $4.7 million, or $(0.45) per basic and diluted share, for the same period in 2025.

As of September 30, 2026, Serina had cash and cash equivalents totaling $19.4 million. The company also reported total revenues of $125,000 for the three months ended September 30, 2026, which consisted entirely of contract revenues. Serina is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology.